Genetic markers displaying highly significant statistical associations with complex phenotypes may not necessarily possess sufficient clinical validity to be useful. Understanding the contribution of these markers beyond readily available clinical biomarkers is particularly important in pharmacogenetics. We demonstrate the utility of genetic testing using the example of warfarin in a multi-ethnic setting comprising of three Asian populations that are broadly representative of the genetic diversity for half of the population in the world, especially as distinct interethnic differences in warfarin dose requirements have been previously established. We confirmed the roles of three wellestablished loci (CYP2C9, VKORC1 and CYP4F2) in explaining warfarin dosage variation in the three Asian populations. In addition, we assessed the relationship between ethnicity and the genotypes of these loci, observing strong correlations at VKORC1 and CYP4F2. Subsequently, we established the additional utility of these genetic factors in predicting warfarin dose beyond ethnicity and clinical biomarkers through performing a series of systematic cross-validation analyses of the relative predictive accuracies of various fixeddose regimen, clinical and genetic models. Through a pharmacogenetics model for warfarin, we show the importance of genetic testing beyond readily available clinical biomarkers in predicting dose requirements, confirming the role of genetic profiling in personalized medicine.
Introduction
Despite the long history of pharmacogenetics, its applications in clinical practice have been slow in coming. Pharmacogenetic research has burgeoned in the last decade, facilitated by the completion of the Human Genome and Hapmap Projects. Currently, evidence of several drug genotype-phenotype associations is well established enough to warrant Food and Drug Administration recommendation for genetic testing (http://www.pharmgkb.org/clinical/index.jsp). It has recently been recognized for complex diseases that the relationship between association P-values and discriminative ability of genetic markers are not necessarily proportional. 1, 2 Therefore, genetic markers should be evaluated by their ability to improve predictive accuracy, or clinical validity. Disappointingly, the genetic signals identified for complex diseases thus far are generally inadequate to be used as disease classifiers despite being replicated across multiple populations and displaying statistically significant effect sizes. 2, 4, 5 As with complex diseases, pharmacogenetic traits are believed to be polygenic, 6 although the observed effects are considerably larger than those established in complex diseases and are likely to involve fewer genes. 7 The advent of affordable genetic profiling thus underscores the progression towards personalized medicine and therapies, by leveraging on clinically relevant information from pharmacogenetic studies in the prediction of drug dosage, metabolism and response.
Clinical utility goes a step further from clinical validity, usually entailing evidence that an intervention (for example, use of pharmacogenetic-guided dosing) improves some clinical outcomes. From a regulatory standpoint, Lesko and Zineh argued that it may be inappropriate to demand evidence of clinical utility before advocating the use of pharmacogenetic testing. 8 Although it is desirable to perform prospective studies to answer questions of clinical utility where feasible, we demonstrate in this paper using the example of warfarin the population impact of genetic factors and their clinical validity from a public health perspective, demonstrating the usefulness of genetic testing beyond clinical biomarkers in providing useful information for predicting the required dosage.
Warfarin, the most widely used anticoagulant for the prevention and treatment of thromboembolic disorders, is a drug with narrow therapeutic index and wide interindividual variability, making it a challenge to administer. The risks associated with overdosage (bleeding) and underdosage (thrombosis) are non-trivial. Clinical factors such as age, weight, gender, diet and certain diseases affect warfarin dose requirements. 9 Several genes are also associated with warfarin maintenance dose variability, including CYP2C9 (*2 and *3) and VKORC1 that have consistently been implicated in multiple populations. [10] [11] [12] [13] [14] [15] [16] Recent evidence also suggested that a non-synonymous variant (rs2108622, V433 M) in CYP4F2 may be clinically relevant although the contribution was modest relative to CYP2C9 and VKORC1. 17, 18 Other genes in the warfarin interactive pathway have been investigated, although results have been inconsistent and the transferability and relevance to multiple populations remain unclear. [18] [19] [20] [21] Before the proliferation of genetic analyses, warfarin dose requirements have been observed to vary between different ethnic and population groups, with Asians requiring lower doses than Caucasians. 22 In the multi-ethnic population of Singapore, Chinese and Malays have been observed to require lower doses compared with Asian Indians. 14, 15 Perhaps not surprising, the frequency of the VKORC1 haplotype associated with high warfarin dosage displayed considerable interethnic variability, and is appropriately more common in populations that require higher warfarin doses. 15, 23, 24 This poses the question whether self-reported ethnicity is a sufficient surrogate for genetic testing or whether genetic information actually possesses additional utility in assessing dose requirements and dynamics.
The extensive literature established on the genetic and clinical factors influencing warfarin dosage make this an ideal case study on the translational nature of pharmacogenetics. Through a systematic investigation of 248 samples recruited from a multi-ethnic setting in Singapore, we explore the clinical relevance of CYP2C9, VKORC1 and CYP4F2 beyond the standard clinical attributes in predicting warfarin dosage. The demography of Singapore comprising of Chinese, Malays and Asian Indians is ideal for assessing the transferability and relevance of genetic findings, as these three population groups broadly represent the genetic diversity across Asia, where almost half of the global population resides in. 24 
Materials and methods

Study population and genotyping
Our study surveyed 248 patients (131 Chinese, 81 Malays and 36 Asian Indians) who were previously enrolled in a study on the pharmacogenetics of warfarin maintenance dose. 14, 15 Briefly, patients with a stable therapeutic international normalized ratio between two and three for at least 3 months were recruited from the anticoagulation clinics at the National University Hospital and Tan Tock Seng Hospital in Singapore between June 2002 and June 2004. Clinical information including age, weight, gender, ethnicity and mean daily warfarin maintenance dose (taken as the mean of two consecutive doses when international normalized ratio were stable) were recorded. The ethnicity of a subject was ascertained accordingly if all four paternal and maternal grandparents belong to the same ethnic group. Ethical consent was granted by the respective Ethics Review Committees of the hospitals, and written-informed consent was obtained from all the participants.
We genotyped rs2108622 in CYP4F2 using PCR and direct sequencing with BigDye Terminator Version 3.1 Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA). CYP2C9*3 14 and VKORC1 381 (rs7196161). 15 were genotyped as previously reported, using direct sequencing and pyrosequencing, respectively. It was previously established that VKORC1 381 alone is sufficient to distinguish between the two common haplotypes H1 and H7 in VKORC1. 16 Gene names mentioned henceforth will refer to the described variants here. CYP2C9*2 was excluded from our survey as this variant is considerably rare in our populations. 14, 16 Statistical analysis Correlation between genes and warfarin maintenance dose. All analyses were performed in R Version 2.11.1. 25 The contributions of CYP2C9*3, VKORC1 and CYP4F2 have been established in this study population previously. 14, 15 We evaluated and confirmed the contribution of these genetic loci in our samples within a regression framework, with the logarithm of the dosage used as the response.
Correlation between ethnicity and genes in explaining warfarin dosage. Given the concurrence between ethnic variation in warfarin dose requirement and interethnic differences in the allele frequency of the surveyed genetic variant in VKORC1, we set out to investigate two hypotheses: (i) whether the three genes are predictive of self-reported ethnicity; and (ii) whether the genes are still useful in explaining warfarin dosage after adjusting for ethnicity. To explore the first hypothesis, we examined the Wright's Fixation Index, Fst, which is a measure of population differentiation. For two populations with allele frequencies denoted as p 1 and p 2 , the Fst is defined as:
For each Fst, we calculated the empirical P-value as the proportion of 1 353 095 single nucleotide polymorphisms in the Singapore Genome Variation Project 24 with Fst values at least as large as the observed statistic using allele frequencies from the clinical sample. We also performed a multinomial regression with the genes as predictors and ethnicity as the response to assess the relative contribution of each gene in explaining ethnicity, and the statistical significance of each gene was evaluated with an analysis of variance. To investigate the second hypothesis, we constructed a linear model between log warfarin dose and the genes, after adjusting for previously established clinical factors like age and weight, 16 and for ethnicity. The additional contribution of the genes beyond age, weight and ethnicity in explaining warfarin dose was assessed with analysis of variance.
Predictive accuracy of warfarin dose requirement from genetic and clinical factors. One important aspect in warfarin pharmacogenetics applications is whether genetic information is useful and sufficient in establishing the dosage of a drug therapy across multiple populations. We investigated the accuracy of the three genes and clinical factors (age and weight) for predicting warfarin dosage in our samples. To achieve this, we performed a cross-validation exercise where 80% of our original 248 samples was used to train the regression model, which is subsequently used to predict the dose requirement for the remaining 20% of the samples. In each cross-validation, we measured two statistics: (i) the proportion of the variance explained by the model (r 2 ) with the training data; and (ii) the proportion of patients where the predicted dose was found within 20% of the actual dose. The second criterion is a clinically accepted margin of inaccuracy, and has commonly been used as a threshold for assessing the dose prediction accuracy. 26 We also included fixed-dose regimens for comparison. Although 5 mg is a common standard starting dose, it is not unusual in clinical practice to give lower doses to Chinese and Malay patients and so a race-specific fixed dose regimen was also included for comparison. We performed 100 iterations of the cross-validation for each model, and eight models involving fixed-dose regimen and various combinations of clinical and genetic factors were considered: 
Results
Our analysis confirmed the association between the three genetic factors CYP2C9*3 (P-value ¼ 1.61 Â 10 À4 ), VKORC1 (P-value ¼ 7.19 Â 10 À6 ) and CYP4F2 (P-value ¼ 3.30 Â 10
À5
) with warfarin maintenance dose, explaining between 7% (CYP2C9*3) and 30% (VKORC1) of the dose variance (Table 1) . Specifically, at VKORC1381, we observed an almost 3 mg difference in dosage between individuals carrying the CC genotype compared with those carrying the TT genotype. This coincides with a significant difference in the distribution of the high dosage T allele between the Indians and both the Chinese and the Malays, with frequency of 11.1%, 34.6% and 87.5% in Chinese, Malays and Asian Indians, respectively. These yield an Fst of 7.8% (empirical P-value ¼ 1.16 Â 10 À3 ) between Chinese and Malays, 29.4% (empirical P-value ¼ 4.12 Â 10
À4
) between Malays and Asian Indians, and 58.4% (empirical P-value ¼ 2.73 Â 10 À5 ) between Chinese and Asian Indians (Table 2) . Although some differences between Indians and the other two ethnic groups were similarly observed at CYP2C9*3 and CYP4F2 (Table 1) , the differentiation as assessed by Fst was much weaker (Table 2 ). There were also no significant distinctions between the Chinese and Malays at CYP2C9*3 and CYP4F2 ( Table 2 ). The multinomial regression between ethnicity and the genotypes of the three genes identified VKORC1 (P-value o10 -16 ) and CYP4F2 (P-value ¼ 4.66 Â 10 À4 ) to be strongly associated with ethnic distribution, but not for CYP2C9*3 (P-value ¼ 0.106).
The observation of a strong correlation between the genotypes of CYP4F2 and VKORC1 with ethnicity poses the question whether there is additional merit in performing genetic testing, as self-reported ethnicity may already function as an effective surrogate to represent the genetic information. We observed that all three genes were additionally important for explaining warfarin dose variation (P-value ranging from 6.2 Â 10 À4 for CYP4F2 to Po10 À16 for VKORC1, Table 3 ), even after adjusting for ethnicity and two other clinical biomarkers (age and weight). In addition, we observe that CYP4F2 significantly contributes in explaining dose variation (P ¼ 2.42 Â 10 À4 ), even after taking into account ethnicity, clinical factors and the two main genetic factors CYP2C9*3 and VKORC1 (Table 3) .
Having established the importance of all three genetic factors for explaining variations in warfarin dose requirements, it is clinically important to investigate the relevance of genetic information, as well as clinical factors, in predicting the required warfarin dosage. Through a crossvalidation procedure where 80% of the samples were used to train a regression model that is subsequently applied to predict the required dosage for the remaining 20% of the samples, we compared the accuracy of the prediction in eight settings involving fixed-dose regimens and different combinations of clinical and genetic factors (Figure 1 , see Materials and methods). Due to the different dose requirements in the three ethnic groups, a standard dose of 5 mg performed worst in terms of accuracy (model A), predicting the dosage for only 25% of the patients within acceptable error margin. As expected, a race-specific fixed dose, where 3 mg is assigned to the Chinese and Malays and 5 mg assigned to the Indians, performed better (model B), yielding very similar predictive accuracies to the use of ethnicity alone to determine dosage (model C). Incorporating clinical variables like age and weight increased the amount of dose variance explained and also the proportion of patients that are accurately predicted (model D), but the improvement was marginal compared with when the genetic factors were incorporated (models E-H). The model incorporating only CYP2C9*3 and VKORC1 (model E) already outperforms models that utilize only clinical variables and ethnicity (models A-D), and the improvement was even more significant when these variables were incorporated in addition to the two genes (model F). The additional contribution of CYP4F2 without (model G) and with (model H) the inclusion of ethnicity marginally increased the amount of dose variance explained. 
Discussion
While large-scale genetic studies in numerous common diseases and complex traits have unveiled an abundance of genomic loci that are associated with these phenotypes, the clinical relevance and utility of these findings in medical genetics have been relatively limited due to the marginal contribution by each locus. This raises the question on the clinical relevance of pharmacogenetics, particularly when current efforts are mainly population-based and there is already ample evidence of dose variation between different population/ethnic groups, suggesting that self-reported population or ethnic membership may be sufficient to act as a natural surrogate to genetic testing. Through a systematic survey of warfarin dose requirements in patients from three major ethnic groups in Singapore (consisting of Chinese, Malays and Asian Indians), we have established the additional contribution that genetic testing can yield beyond easily-assayed clinical biomarkers like age, weight and gender, as well as self-reported ethnicity. Warfarin dose requirement is an ideal example to explore the value of genetic testing, as several studies have highlighted the association between ethnic groups in South-East Asia and dose variation. [26] [27] [28] Our findings suggest that even within each ethnic group, genetic information from three loci (VKORC1, CYP2C9 and CYP4F2) is still important in assessing warfarin dosage requirements. Our findings further suggest that the broad classification of individuals according to self-reported ethnicity can result in under/over-dosing, with the severity and fraction of affected individuals depending on the ethnic group. Only one other study has evaluated the additional role of CYP4F2 in terms of prediction accuracy but the authors only reported the proportion of variance (r 2 ) explained. 29 Our positive findings for CYP4F2 reinforced the functional role of the locus in explaining warfarin dosage variation, increasing the r 2 by 3% even after including VKORC1 and CYP2C9.
Out of the three loci we surveyed, the genotypes for VKORC1 was most predictive of ethnicity, whereas the associations between ethnicity and the genotypes of CYP2C9 and CYP4F2 were considerably weaker. Our finding for VKORC1 concurred with a previous genome-wide comparison of genetic variability across the Chinese, Malays and Indians in Singapore, where VKORC1 was among the 10 most differentiated regions across the genome between these three ethnicities. 24 Despite the strong correlation between VKORC1 and ethnicity, all the genes we surveyed contribute additional predictive information for warfarin dose requirements on top of ethnicity. In fact, 85-90% of our genetic variation is due to differences within ethnic groups and only 10-15% due to differences between ethnic groups. 30 This suggests that although self-reported ethnicity is likely to be statistically associated with warfarin dose variation, it is unlikely to be clinically useful on its own for predicting dose requirements, nor as a surrogate for the genetic factors that are involved in warfarin dose response. This finding concurs with those of a previous study, which explored the contribution of race to genotypic variance across three pathways (irinotecan, 5-FU and insulin) in the four Hapmap populations using hierarchical clustering and principal component analysis. 31 Self-reported population or ethnic membership is likely to be even less useful with increasing rates of interethnic marriages, particularly in multi-ethnic societies like Singapore, as self-reported ethnicity is likely to be misleading in the presence of genetic admixture.
The main objective of the predictive accuracy calculations here was not to evaluate specific dosing algorithms but to demonstrate the clinical validity of genetic factors to predict warfarin dosing in our population. The relative contribution of genetic information beyond conveniently attained clinical information such as age and weight will be important in deciding the importance of genetic testing in pharmacogenetics. Studies assessing the prediction accuracy of warfarin dosing algorithms use measures such as mean absolute error, coefficient of determination (r 2 ) and proportion of patients with predicted dose within certain limits of the actual dose ( ± 20% or ± 1 mg per day). 26, 29, 32, 33 We have used similar measures as these are easily interpretable and allow direct comparisons with published findings. However, each measure represents only some aspect of dose prediction. This may explain why as genetic variables are added on to clinical variables, the r 2 increases considerably but the proportion of patients with predicted dose within ± 20% actual dose only increases slightly. With the second measure, improvements in predictions that fall outside this range are undetected, yet these are likely where most of the improvements will be.
Using these measures our results show that the prediction accuracy of clinical and genetic factors combined (model F) compare well across different populations in terms of r 2 and proportion of patients with predicted dose within ±20% actual dose. 26, 29, 32, 33 The clinical relevance of genetic factors was similar to the observations by the International Warfarin Pharmacogenetics Consortium (IWPC), who similarly reported that genetic factors improved the prediction accuracy for an additional 5% of the samples beyond nongenetic biomarkers like age and weight. 26 Importantly, our findings conclude that information from genetic testing is superior to clinical biomarkers and self-reported population/ethnic membership for predicting warfarin dose requirements.
Ultimately, the importance of pharmacogenetics lies in the relative contribution that genetic information can provide beyond conveniently attained clinical biomarkers such as age, weight, gender and self-reported population group. We have deliberately selected an easy target, warfarin dosing, to evaluate the value of genetic testing, as the dose requirement for warfarin has been well catalogued to be influenced by numerous clinical and genetic factors, including self-reported ethnicity in South-East Asia. Warfarin thus serves as a model example to evaluate whether genetic testing is still relevant when self-reported ethnicity may appear to serve as a natural surrogate for genetic information. Our findings reinforce the importance of pharmacogenetics, and this is expected to be important as progress in medical genomics inexorably converges towards personalized medication.
